Gp130-mediated signalling as a therapeutic target

Expert Opinion on Therapeutic Targets

Volumn 4, Issue 4, 2000, Pages 459-479

  Ohtani, Takuya ^a   Ishihara, Katsuhiko ^b   Atsumi, Toru ^b   Yoshida, Yuichi ^b   Nishida, Keigo ^b   Narimatsu, Masahiro ^b   Shirogane, Takahiro ^b   Hibi, Masahiko ^b   Hirano, Toshio ^b  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Castlemans disease; CNTF; Crohn's disease; cytokine; Gab; gp130; IL 11; IL 6; Kaposi's sarcoma; LIF; MAPK; multiple myeloma; negative regulation; OSM; PIAS; rheumatoid arthritis; SHP2; signal transduction; SOCS; STAT3

Indexed keywords

EID: 14244253255     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.4.4.459     Document Type: Review

References (202)

1. HIRANOT, YASUKAWAK, HARADAHetal.: Complemen tary DNAfor a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature (1986) 324 (6092):73-76.
2. HIRANO T: Interleukin 6 and its receptor: ten years later. Int. Rev. Immunol. (1998) 16 (3-4):249-284.
3. TERANISHI T, HIRANO T, ARIMA N, ONOUE K: Human helper T cell factor(s) (ThF). II. Induction of IgG production in B lymphoblastoid cell lines and identification of T cell replacing factor (TRF)-like factor(s).J. Immunol. (1982) 128:1903-1908.
4. MAY LT, HELFGOTT DC, SEHGAL PB: Anti-P-interferon antibodies inhibit the increased expression of HLA-B7 mRNA in tumor necrosis factor-treated human fibroblasts: Structural studies of the P2 interferon involved. Proc. Natl. Acad. Sci. USA (1986) 83:8957-8961.
5. ZILBERSTEIN A, RUGGIERI R, KORN JH, REVEL M: Structure and expression of cDNA and genes for human interferon-P-2, a distinct species inducible by growth-stimulatory cytokines. EMBO J. (1986) 5 (10):2529-2537.
6. HAEGEMAN G, CONTENT J, VOLCKAERT G et al.: Structural analysis of the sequence encoding for an inducible 26-kDa protein in human fibroblasts. Eur. J. Biochem. (1986) 159:625-632.
7. VAN SNICK J: Interleukin-6: an overview. Ann. Rev Immunol. (1990) 8:253-278.
8. SEHGAL PB, GRIENGER G, TOSATO G: Regulation of the acute phase and immune responses: interleukin-6. Ann. NY Acad. Sci. (1989) 1-583.
9. HIRANO T: Interleukin 6. In: The Cytokine Handbook (3rd Edition). Thomson AW (Ed.), Academic Press (1998):197-228.
10. YAMASAKI K, TAGA T, HIRATA Y et al: Cloning and expression of the human interleukin-6 (BSF-2/IFNP 2) receptor. Science (1988) 241 (4867):825-828.
11. TAGA T, HIBI M, HIRATA Y et al: Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130. Cell (1989) 58 (3):573-581.
12. HIBI M, MURAKAMI M, SAITO M et al.: Molecular cloning and expression of an IL-6 signal transducer, gp130. Cell (1990) 63 (6):1149-1157.
13. HIRANO T, NAKAJIMAK, HIBI M: Signaling mechanisms through gp130: a model of the cytokine system. Cytokine Growth Factor Rev. (1997) 8(4):241-252.
14. SENALDI G, VARNUM BC, SARMIENTO U et al: Novel neurotrophin-1/B cell-stimulating factor-3: a cytokine of the IL-6 family. Proc. Natl. Acad. Sci. USA (1999) 96 (20):11458-11463.
15. HEINRICH PC, BEHRMANN I, MULLER-NEWEN G, SCHAPER F, GRAEVE L: Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochem. J. (1998) 334(Pt 2):297-314.
16. HIRANO T, TAGA T, YASUKAWA K et al: Human B cell differentiation factor defined by an anti-peptide antibody and its possible role in autoantibody production. Proc. Natl. Acad. Sci. USA (1987) 84:228-231.
17. HIRANO T, MATSUDA T, TURNER M et al: Excessive production of interleukin 6/B cell stimulatory factor-2 in rheumatoid arthritis. Eur. J. Immunol. (1988) 18 (11):1797-1801.
18. WARING PM, CARROLL GJ, KANDIAH DA, BUIRSKI G, METCALF D: Increased levels of leukemia inhibitory factor in synovial fluid from patients with rheumatoid arthritis and other inflammatory arthritides. Arthritis Rheum. (1993) 36 (7):911-915.
19. OKAMOTO H, YAMAMURA M, MORITA Y et al: The synovial expression and serum levels of interleukin-6, interleukin-11, leukemia inhibitory factor and oncostatin M in rheumatoid arthritis. Arthritis Rheum. (1997) 40 (6):1096-1105.
20. KEUL R, HEINRICH PC, MULLER-NEWEN G, MULLER K, WOO P: Apossible role for soluble IL-6 receptor in the pathogenesis of systemic onset juvenile chronic arthritis. Cytokine (1998) 10(9)729-734.
21. KAWANO M, HIRANO T, MATSUDA T et al: Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature (1988) 332 (6159):83-85.
22. KLEIN B, ZHANG XG, LU ZY, BATAILLE R: Interleukin-6 in human multiple myeloma. Blood (1995) 85 (4):863-872.
23. WIERZBOWSKA A, URBANSKA-RYS H, ROBAK T: Circulating IL-6-type cytokines and sIL-6Rin patients with multiple myeloma. Br. J. Haematol. (1999) 105 (2)412-419.
24. HORII Y, MURAGUCHI A, IWANO M et al: Involvement of IL-6 in mesangial proliferative glomerulonephritis. J. Immunol. (1989) 143(12):3949-3955.
25. YOSHIZAKI K, MATSUDA T, NISHIMOTO N et al.: Pathogenic significance of interleukin-6 (IL6/BSF-2) in Castleman's disease. Blood (1989) 74 (4):1360-1367.
26. JILKA RL, HANGOC G, GIRASOLE G et al: Manolagas SC Increased osteoclast development after estrogen loss: mediation by interleukin-6. Science (1992) 257:88-91.
27. ATREYA R, MUDTER J, FINOTTO S et al: Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in crohn disease and experimental colitis in vivo. Nature Med. (2000) 6 (5):583-588.
28. MINSHALL E, CHAKIR J, LAVIOLETTE M et al: IL11 expression is increased in severe asthma: association with epithelial cells and eosinophils. J. Allergy Clin. Immunol. (2000) 105(2 Pt 1):232-238.
29. JAFFE HW, PELLETT PE: Human herpesvirus 8 and Kaposi's sarcoma-some answers, more questions. N. Engl. J. Med. (1999) 340 (24):1912-1913.
30. SUEMATSUS, MATSUDAT, AOZASAKetal.: IgG1 plasma-cytosis in interleukin 6 transgenic mice. Proc. Natl. Acad. Sci. USA (1989) 86(19)7547-7551.
31. SUEMATSU S, MATSUSAKA T, MATSUDA T et al: Genera tion of plasmacytomas with the chromosomal translo cation t(12;15) in interleukin 6 transgenic mice. Proc. Natl. Acad. Sci. USA (1992) 89 (1):232-235.
32. HIRANO T, ISHIHARA K, HIBI M: Roles of STAT3 in mediatingthe cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors. Oncogene (2000) 19:2548-2556.
33. HIRANO T: Interleukin 6 (IL-6) and its receptor: their role in plasma cell neoplasias. Int. J. Cell Cloning (1991) 9 (3):166-184.
34. SHEN MM, SKODA RC, CARDIFF RD etal: Expression of LIFin transgenic mice results in altered thymic epithelium and apparent interconversion of thymic and lymph node morphologies. EMBO J. (1994) 13 (6):1375-1385.
35. PETERS M, SCHIRMACHER P, GOLDSCHMITT J et al: Extramedullary expansion of hematopoietic progenitor cells in interleukin (IL)-6-sIL-6R double transgenic mice. J. Exp. Med. (1997) 185:755-766.
36. MAIONE D, DI CARLO E, LI W etal: Coexpression of IL-6 and soluble IL-6R causes nodular regenerative hyperplasia and adenomas of the liver. EMBOJ. (1998) 17(19)5588-5597.
37. KOPF M, BAUMANN H, FREER G etal: Impaired immune and acute-phase responses in interleukin-6-deficient mice. Nature (1994) 368 (6469):339-342.
38. KOPF M, HERREN S, WILES MV, PEPYS MB, KOSCO-VILBOIS MH: Interleukin 6 influences germinal center development and antibody production viaa contribution of C3 complement component. J. Exp. Med. (1998) 188 (10):1895-1906.
39. KOPF M, RAMSAY A, BROMBACHER F et al: Pleiotropic defects of IL-6-deficient mice including early hematopoiesis, T and B cell function and acute phase responses. Ann. NY Acad. Sci. (1995) 762:308-318.
40. LADEL CH, BLUM C, DREHER A etal: Lethal tuberculosis in interleukin-6-deficient mutant mice. Infect Immun. (1997) 65 (11):4843-4849.
41. ROMANI L, MENCACCI A, CENCI E et al: Impaired neutrophil response and CD4+ Thelper cell 1 development in interleukin 6-deficient mice infected with Candida albicans. J. Exp. Med. (1996) 183 (4):1345-1355.
42. SUZUKI Y, RANI S, LIESENFELD O et al: Impaired resistance to the development of toxoplasmic encephalitis in interleukin-6-deficient mice. Infect Immun. (1997) 65 (6):2339-2345.
43. DALRYMPLE SA, LUCIAN LA, SLATTERY R et al.: Interleukin-6-deficient mice are highly susceptible to Listeria monocytogenes infection: correlation with inefficient neutrophilia. Infect. Immun. (1995) 63(6):2262-2268.
44. ALONZI T, FATTORI E, LAZZARO D et al.: Interleukin 6 is required for the development of collagen-induced arthritis. J. Exp. Med. (1998) 187(4):461-468.
45. SASAI M, SAEKI Y, OHSHIMA S et al.: Delayed onset and reduced severity of collagen-induced arthritis in interleukin-6-deficient mice. Arthritis Rheum. (1999) 42(8):1635-1643.
46. TAKAGI N, MIHARA M, MORIYA Y et al.: Blockage of interleukin-6 receptor ameliorates joint disease in murine collagen-induced arthritis. Arthritis Rheum. (1998) 41(12):2117-2121.
47. MENDEL I, KATZ A, KOZAK N, BEN-NUN A, REVEL M: Interleukin-6 functions in autoimmune encephalo-myelitis: a study in gene-targeted mice. Eur. J. Immunol. (1998) 28(5):1727-1737.
48. OKUDA Y, SAKODA S, BERNARD CC et al.: IL-6-deficient mice are resistant to the induction of experimental autoimmune encephalomyelitis provoked by myelin oligodendrocyte glycoprotein. Int. Immunol. (1998) 10(5):703-708.
49. SAMOILOVA EB, HORTON JL, HILLIARD B, LIU TS, CHEN Y: IL-6-deficient mice are resistant to experimental autoimmune encephalomyelitis: roles of IL-6 in the activation and differentiation of autoreactive T cells. J. Immunol. (1998) 161(12):6480-6486.
50. ESCARY JL, PERREAU J, DUMENIL D, EZINE S, BRULET P: Leukaemia inhibitory factor is necessary for maintenance of haematopoietic stem cells and thymocyte stimulation. Nature (1993) 363(6427):361-364.
51. MASU Y, WOLF E, HOLTMANN B et al.: Disruption of the CNTF gene results in motor neuron degeneration. Nature (1993) 365(6441):27-32.
52. MORITZ RL, WARD LD, TU GF et al.: The N-terminus of gp130 is critical for the formation of the high-affinity interleukin-6 receptor complex. Growth Factors (1999) 16(4):265-278.
53. HAMMACHER A, RICHARDSON RT, LAYTON JE et al.: The immunoglobulin-like module of gp130 is required for signaling by interleukin-6, but not by leukemia inhibitory factor. J. Biol. Chem. (1998) 273(35):22701-22707.
54. VOLLMER P, OPPMANN B, VOLTZ N, FISCHER M, ROSE-JOHN S: A role for the immunoglobulin-like domain of the human IL-6 receptor. Intracellular protein transport and shedding. Eur. J. Biochem. (1999) 263(2):438-446.
55. HORSTEN U, MULLER-NEWEN G, GERHARTZ C et al.: Molecular modeling-guided mutagenesis of the extracellular part of gp130 leads to the identification of contact sites in the interleukin-6 (IL-6). IL-6 receptor.gp130 complex. J. Biol. Chem. (1997) 272(38):23748-23757.
56. OLIVIER C, AUGUSTE P, CHABBERT M et al.: Identification of a gp130 cytokine receptor critical site involved in oncostatin M response. J. Biol. Chem. (2000) 275(8):5648-5656.
57. KURTH I, HORSTENU, PFLANZ Set al.: Importance ofthe membrane-proximal extracellular domains for activation of the signal transducer glycoprotein 130. J. Immunol. (2000) 164 (1):273-282.
58. LUTTICKEN C, WEGENKA UM, YUAN J etal: Association of transcription factor APRF and protein kinase Jak1 with the interleukin-6 signal transducer gp130. Science (1994) 263 (5143):89-92.
59. STAHL N, BOULTON TG, FARRUGGELLA T etal: Association and activation of Jak-Tyk kinases by CNTF-LIF-OSM-IL-6 P receptor components. Science (1994) 263 (5143):92-95.
60. FUKADA T, HIBI M, YAMANAKA Y etal: Two signals are necessary for cell proliferation induced by a cytokine receptor gp130: involvement of STAT3 in anti-apoptosis. Immunity (1996) 5 (5):449-460.
61. STAHL N, FARRUGGELLA TJ, BOULTON TG etal: Choice of STATs and other substrates specified by modular tyrosine-based motifs in cytokine receptors. Science (1995) 267 (5202):1349-1353.
62. YAMANAKA Y, NAKAJIMAK, FUKADAT, HIBI M, HIRANO T: Differentiation and growth arrest signals are generated through the cytoplasmic region of gp130 that is essential for Stat3 activation. EMBO J. (1996) 15 (7):1557-1565.
63. YOSHIDA K, TAGA T, SAITO M etal: Targeted disruption of gp130, a common signal transducer for the interleukin 6 family of cytokines, leads to myocardial and hematological disorders. Proc. Natl Acad. Sci. USA (1996) 93 (1):407-411.
64. HIROTA H, CHEN J, BETZ UA et al: Loss of a gp130 cardiac muscle cell survival pathway is a critical event in the onset of heart failure during biomechanical stress. Cell (1999) 97 (2):189-198.
65. OHTANI T, ISHIHARA K, ATSUMI T et al: Dissection of signaling cascades through gp130 in vivo: reciprocal roles for STAT3-and SHP2-mediated signals in immune responses. Immunity (2000) 12 (1):95-105.
66. KAWASAKI K, GAO YH, YOKOSE S etal: Osteoclasts are present in gp130-deficient mice. Endocrinology (1997) 138 (11):4959-4965.
67. KUMANOGOH A, MARUKAWA S, KUMANOGOH T etal: Impairment of antigen-specific antibody production in transgenic mice expressing a dominant-negative form of gp130. Proc. Natl. Acad. Sci. USA (1997) 94(6):2478-2482.
68. BETZ UAK, BLOCH W, VAN DEN BROEK M etal: Postna-tally induced inactivation of gp130 in mice results in neurological, cardiac, hematopoietic, immunological, hepatic and pulmonary defects. J. Exp. Med. (1998) 188 (10):1955-1965.
69. LI M, SENDTNER M, SMITH A: Essential function of LIF receptor in motor neurons. Nature (1995) 378 (6558):724-727.
70. DECHIARA TM, VEJSADA R, POUEYMIROU WT etal: Mice lacking the CNTF receptor, unlike mice lacking CNTF, exhibit profound motor neuron deficit at birth. Cell (1995) 83:313-322.
71. WARE CB, HOROWITZ MC, RENSHAW BR etal: Targeted disruption of the low-affinity leukemia inhibitory factor receptor gene causes placental, skeletal, neural and metabolic defects and results in perinatal death. Development (1995) 121 (5):1283-1299.
72. TONKS NK, NEEL BG: From form to function: signaling by protein tyrosine phosphatases. Cell (1996) 87 (3):365-368.
73. FENG GS, HUI CC, PAWSON T: SH2-containing phosphotyrosine phosphatase as a target of protein-tyrosine kinases. Science (1993) 259 (5101):1607-1611.
74. VOGEL W, LAMMERS R, HUANG J, ULLRICH A: Activation of a phosphotyrosine phosphatase by tyrosine phosphorylation. Science (1993) 259(5101):1611-1614.
75. BENNETT AM, TANG TL, SUGIMOTO S, WALSH CT, NEEL BG: Protein-tyrosine- phosphatase SHPTP2 couples platelet-derived growth factor receptor P to Ras. Proc Natl. Acad. Sci. USA (1994) 91 (15):7335-7339.
76. LI W, NISHIMURA R, KASHISHIAN Aetal: Anew function for a phosphotyrosine phosphatase: linking GRB2-Sos to a receptor tyrosine kinase. Mol Cell. Biol (1994) 14(1):509-517.
77. KIM H, HAWLEY TS, HAWLEY RG, BAUMANN H: Protein tyrosine phosphatase 2 (SHP-2) moderates signaling by gp130 but is not required for the induction of acute-phase plasma protein genes in hepatic cells. Mol Cell. Biol (1998) 18 (3):1525-1533.
78. SYMES A, STAHL N, REEVES SA et al: The protein tyrosine phosphatase SHP-2 negatively regulates ciliary neurotrophic factor induction of gene expression. Curr. Biol. (1997) 7 (9):697-700.
79. HOF P, PLUSKEY S, DHE-PAGANON S, ECK MJ, SHOELSON SE: Crystal structure of the tyrosine phosphatase SHP-2. Cell (1998) 92(4):441-450.
80. BENNETT AM, HAUSDORFF SF, O'REILLY AM, FREEMAN RM, NEEL BG: Multiple requirements for SHPTP2 in epidermal growth factor-mediated cell cycle progression. Mol Cell. Biol. (1996) 16 (3):1189-1202.
81. NOGUCHI T, MATOZAKI T, HORITA K, FUJIOKA Y, KASUGA M: Role of SH-PTP2, a protein-tyrosine phosphatase with Src homology 2 domains, in insulin-stimulated Ras activation. Mol. Cell. Biol (1994) 14(10):6674-6682.
82. TANG TL, FREEMAN RM, JR., O'REILLY AM, NEEL BG, SOKOL SY: The SH2-containing protein-tyrosine phosphatase SH-PTP2 is required upstream of MAP kinase for early Xenopus development. Cell (1995) 80(3):473-483.
83. HOLGADO-MADRUGA M, EMLET DR, MOSCATELLO DK, GODWIN AK, WONG AJ: A Grb2-associated docking protein in EGF-and insulin-receptor signalling. Nature (1996) 379 (6565):560-564.
84. RAABE T, RIESGO-ESCOVAR J, LIU X etal: DOS, a novel pleckstrin homology domain-containing protein required for signal transduction between sevenless and Ras1 in Drosophila. Cell (1996) 85 (6):911-920.
85. HERBST R, CARROLL PM, ALLARD JD et al: Daughter of sevenless is a substrate of the phosphotyrosine phosphatase Corkscrew and functions during sevenless signaling. Cell (1996) 85 (6):899-909.
86. GU H, PRATT JC, BURAKOFF SJ, NEEL BG: Cloning of p97/Gab2,the major SHP2-bindingprotein in hematopoietic cells, reveals a novel pathway for cytokine-induced gene activation. Mol. Cell (1998) 2 (6):729-740.
87. NISHIDA K, YOSHIDA Y, ITOH M et al: Gab-family adapter proteins act downstream of cytokine and growth factor receptors and T and B cell antigen receptors. Blood (1999) 93 (6):1809-1816.
88. TAKAHASHI-TEZUKA M, YOSHIDA Y, FUKADA T et al: Gab1 acts as an adapter molecule linking the cytokine receptor gp130 to ERK mitogen-activated protein kinase. Mol. Cell. Biol. (1998) 18 (7):4109-4117.
89. HIBI M, HIRANO T: Gab-family adapter molecules in signal transduction of cytokine and growth factor receptors and Tand B cell antigen receptors. Leukemia Lymphoma (2000) 37 (3-4):299-307.
90. ITOH M, YOSHIDA Y, NISHIDA K etal: Arole of Gab1 for heart, placenta and skin development and growth factors-and cytokines-induced ERK MAP kinase activation. Mol Cell. Biol. (2000) 20 (10):3695-3704.
91. FUKADA T, OHTANI T, YOSHIDA Y et al: STAT3 orchestrates contradictory signals in cytokine-induced G1 to S cell-cycle transition. EMBOJ. (1998) 17 (22):6670-6677.
92. IHARA S, NAKAJIMA K, FUKADA T et al.: Dual control of neurite outgrowth by STAT3 and MAP kinase in PC12 cells stimulated with interleukin-6. EMBO J. (1997) 16(17):5345-5352.
93. HEMMANN U, GERHARTZ C, HEESEL B etal: Differential activation of acute phase response factor/Stat3 and Stat1 via the cytoplasmic domain of the interleukin 6 signal transducer gp130. II. Src homology SH2 domains define the specificity of stat factor activation. J. Biol Chem. (1996) 271 (22):12999-13007.
94. DARNELL JE, JR., KERR IM, STARK GR: Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science (1994) 264(5164):1415-1421.
95. DARNELL JE, JR.: STATs and gene regulation. Science (1997) 277(5332):1630-1635.
96. IHLE JN, KERR IM: Jaks and Stats in signaling by the cytokine receptor superfamily. Trends Genet. (1995) 11(2):69-74.
97. IHLE JN: STATs: signal transducers and activators of transcription. Cell (1996) 84(3):331-334.
98. GERHARTZ C, HEESEL B, SASSE J et al.: Differential activation of acute phase response factor/STAT3 and STAT1viathe cytoplasmic domain ofthe interleukin 6 signal transducer gp130. I. Definition of a novel phosphotyrosine motif mediating STAT1 activation. J. Biol. Chem. (1996) 271(22):12991-12998.
99. NIWA H, BURDON T, CHAMBERS I, SMITH A: Self-renewal of pluripotent embryonic stem cells is mediated via activation of STAT3. Genes Dev. (1998) 12(13):2048-2060.
100. SCHMITZ J, DAHMEN H, GRIMM Cet al.: The cytoplasmic tyrosine motifs in full-length glycoprotein 130 have different roles in IL-6 signal transduction. J. Immunol. (2000) 164(2):848-854.
101. DITTRICH E, HAFT CR, MUYS L, HEINRICH PC, GRAEVE L: A di-leucine motif and an upstream serine in the interleukin-6 (IL-6) signal transducer gp130 mediate ligand-induced endocytosis and down-regulation of the IL-6 receptor. J. Biol. Chem. (1996) 271(10):5487-5494.
102. NAKAJIMA K, YAMANAKA Y, NAKAE K et al.: A central role for Stat3 in IL-6-induced regulation of growth and differentiation in M1 leukemia cells. EMBO J. (1996) 15(14):3651-3658.
103. NAKASHIMA K, YANAGISAWA M, ARAKAWA H et al.: Synergistic signaling in fetal brain by STAT3-Smad1 complex bridged by p300. Science (1999) 284(5413):479-482.
104. BONNI A, SUN Y, NADAL-VICENS M et al.: Regulation of gliogenesis in the central nervous system by the JAK-STAT signaling pathway. Science (1997) 278(5337):477-483.
105. MIGONE TS, LIN JX, CERESETO A et al.: Constitutively activated Jak-STAT pathway in T cells transformed with HTLV-I. Science (1995) 269(5220):79-81.
106. YU CL, MEYER DJ, CAMPBELL GS et al.: Enhanced DNA-binding activity of a Stat3-related protein in cells transformed by the Src oncoprotein. Science (1995) 269(5220):81-83.
107. TURKSON J, BOWMAN T,GARCIA Ret al.: Stat3 activation by Src induces specific gene regulation and is required for cell transformation. Mol. Cell. Biol. (1998) 18(5):2545-2552.
108. DANIAL NN, PERNIS A, ROTHMAN PB: Jak-STAT signaling induced by the v-abl oncogene. Science (1995) 269 (5232):1875-1877.
109. HILBERT DM, MIGONE TS, KOPF M, LEONARD WJ, RUDIKOFF S: Distinct tumorigenic potential of abl and raf in B cell neoplasia: abl activates the IL-6 signaling pathway. Immunity (1996) 5(1):81-89.
110. ILARIA RL, JR., VANETTEN RA: P210 and P190(BCR/ABL) induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members. J. Biol. Chem. (1996) 271 (49):31704-31710.
111. BESSERD, BROMBERG JF, DARNELLJE, JR., HANAFUSAH: A single amino acid substitution in the v-Eyk intracellular domain results in activation of Stat3 and enhances cellular transformation. Mol. Cell. Biol. (1999) 19 (2):1401-1409.
112. RAM PT, HORVATH CM, IYENGAR R: Stat3-mediated transformation of NIH-3T3 cells by the constitutively active Q205L Goto protein. Science (2000) 287 (5450):142-144.
113. CATLETT-FALCONE R, LANDOWSKI TH, OSHIRO MM et al: Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity (1999) 10(1):105-115.
114. BROMBERG JF, HORVATH CM, BESSER D, LATHEM WW, DARNELL JE, JR.: Stat3 activation is required for cellular transformation by v-src. Mol. Cell. Biol. (1998) 18 (5):2553-2558.
115. BROMBERG JF, WRZESZCZYNSKA MH, DEVGAN G etal: Stat3 as an oncogene. Cell (1999) 98 (3):295-303.
116. NIU G, HELLER R, CATLETT-FALCONE R et al: Gene therapy with dominant-negative Stat3 suppresses growth of the murine melanoma B16 tumor in vivo. Cancer Res. (1999) 59 (20):5059-5063.
117. BORSELLINO N, BONAVIDA B, CILIBERTO G et al: Blocking signaling through the Gp130 receptor chain by interleukin-6 and oncostatin M inhibits PC-3 cell growth and sensitizes the tumor cells to etoposide and cisplatin-mediated cytotoxicity. Cancer (1999) 85(1):134-144.
118. HOBISCH A, EDER I.E., PUTZ T et al: Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor. Cancer Res. (1998) 58(20)4640-4645.
119. QIU Y, RAVI L, KUNG HJ: Requirement of ErbB2 for signalling by interleukin-6 in prostate carcinoma cells. Nature (1998) 393 (6680):83-85.
120. QIU Y, ROBINSON D, PRETLOW TG, KUNG HJ: Etk/Bmx, a tyrosine kinase with a pleckstrin-homology domain, is an effector of phosphatidylinositol 3'-kinase and is involved in interleukin 6-induced neuroendocrine differentiation of prostate cancer cells. Proc. Natl. Acad. Sci. USA (1998) 95 (7):3644-3649.
121. TAKEDAK, KAISHO T, YOSHIDA N etal: Stat3 activation is responsible for IL-6-dependent T cell proliferation through preventing apoptosis: generation and characterization of T cell-specific Stat3-deficient mice. J. Immunol. (1998) 161(9)4652-4660.
122. KARRAS JG, WANGZ, HUO L etal: Signal transducer and activator of transcription-3 (STAT3) is constitutively activated in normal, self-renewing B-1 cells but only inducibly expressed in conventional Blymphocytes. J. Exp. Med. (1997) 185(6):1035-1042.
123. SHIROGANE T, FUKADA T, MULLER JM etal: Synergistic roles for Pim-1 and c-Myc in STAT3-mediated cell cycle progression and antiapoptosis. Immunity (1999) 11 (6):709-719.
124. KIUCHI N, NAKAJIMA K, ICHIBA M et al: STAT3 is required for the gp130-mediated full activation of the c-myc gene. J. Exp. Med. (1999) 189 (1):63-73.
125. NAKASHIMAK, WIESES, YANAGISAWA M etal: Developmental requirement of gp130 signaling in neuronal survival and astrocyte differentiation. J. Neurosci. (1999) 19(13):5429-5434.
126. CHUNG CD, LIAO J, LIU B et al: Specific inhibition of Stat3 signal transduction by PIAS3. Science (1997) 278 (5344):1803-1805.
127. LIU B, LIAO J, RAO X etal: Inhibition of Stat1-mediated gene activation by PIAS1. Proc. Natl. Acad. Sci. USA (1998) 95(18):10626-10631.
128. NICHOLSON SE, WILLSON TA, FARLEY A et al.: Mutational analyses of the SOCS proteins suggest a dual domain requirement but distinct mechanisms for inhibition of LIFand IL-6 signal transduction. EMBOJ. (1999) 18(2):375-385.
129. STARR R, WILLSON TA, VINEY EM et al: A family of cytokine-inducible inhibitors of signalling. Nature (1997) 387 (6636):917-921.
130. ENDO TA, MASUHARA M, YOKOUCHI M et al: A new protein containing an SH2 domain that inhibits JAK kinases. Nature (1997) 387 (6636):921-924.
131. NAKA T, NARAZAKI M, HIRATA M et al: Structure and function of anew STAT-induced STATinhibitor. Nature (1997) 387 (6636):924-929.
132. YOSHIMURA A, OHKUBO T, KIGUCHI T et al: A novel cytokine-inducible gene CIS encodes an SH2-containing protein that binds to tyrosine-phosphorylated interleukin 3 and erythropoietin receptors. EMBOJ. (1995) 14 (12):2816-2826.
133. YASUKAWA H, MISAWA H, SAKAMOTO H et al: The JAK-binding protein JAB inhibits Janus tyrosine kinase activity through binding in the activation loop. EMBOJ. (1999) 18(5):1309-1320.
134. SCHMITZ J, WEISSENBACH M, HAAN S, HEINRICH PC, SCHAPER F: SOCS3 exerts its inhibitory function on interleukin-6 signal transduction through the SHP2 recruitment site of gp130. J. Biol. Chem. (2000) 275 (17):12848-12856.
135. NICHOLSON SE, DESOUZAD, FABRI LJ etal: Suppressor of cytokine signaling-3 preferentially binds to the SHP-2-binding site on the shared cytokine receptor subunit gp130. Proc. Natl. Acad. Sci. USA (2000) 97(12):6493-6498.
136. SENGUPTA TK, TALBOT ES, SCHERLE PA, IVASHKIV LB: Rapid inhibition of interleukin-6 signaling and Stat3 activation mediated by mitogen-activated protein kinases. Proc. Natl. Acad. Sci. USA (1998) 95 (19):11107-11112.
137. JAIN N, ZHANG T, FONG SL, LIM CP, CAO X: Repression of Stat3 activity by activation of mitogen-activated protein kinase (MAPK). Oncogene (1998) 17(24):3157-3167.
138. SIEWERT E, MULLER-ESTERL W, STARR R, HEINRICH PC, SCHAPER F: Different protein turnover of interleukin-6-type cytokine signalling components. Eur. J. Biochem. (1999) 265 (1):251-257.
139. ADAMS TE, HANSEN JA, STARR R etal: Growth hormone preferentially induces the rapid, transient expression of SOCS-3, a novel inhibitor of cytokine receptor signaling. J. Biol. Chem. (1998) 273 (3):1285-1287.
140. LOSMAN JA, CHEN XP, HILTON D, ROTHMAN P: Cutting edge: SOCS-1 is a potent inhibitor of IL-4 signal transduction. J. Immunol. (1999) 162 (7):3770-3774.
141. DICKENSHEETS HL, DONNELLY RP: Inhibition of IL-4-inducible gene expression in human monocytes by Type I and Type II interferons. J. Leukoc. Biol. (1999) 65 (3):307-312.
142. MARINE JC, TOPHAM DJ, MCKAY C et al.: SOCS1 deficiency causes a lymphocyte-dependent perinatal lethality. Cell (1999) 98 (5):609-616.
143. ALEXANDER WS, STARR R, FENNER JE et al: SOCS1 is a critical inhibitor of interferon y signaling and prevents the potentially fatal neonatal actions of this cytokine. Cell (1999) 98 (5):597-608.
144. MARINE JC, MCKAY C, WANG D etal: SOCS3 is essential in the regulation of fetal liver erythropoiesis. Cell (1999) 98 (5):617-627.
145. CIAPPONI L, GRAZIANI R, PAONESSA G etal: Definition of a composite binding site for gp130 in human interleukin-6. J. Biol. Chem. (1995) 270 (52):31249-31254.
146. KALLEN K-J, GALLE PR, ROSE-JOHN S: New develop ments in IL-6 dependent biology and therapy: where do we stand and what are the options? Exp. Opin. Invest Drugs (1999) 8(9):1327-1349.
147. BRAVO J, HEATH JK: New EMBO members' review: receptor recognition by gp130 cytokines. EMBO J. (2000) 19(11):2399-2411.
148. KLEIN B, WIJDENES J, ZHANG XG et al.: Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia. Blood (1991) 78 (5):1198-1204.
149. BECK JT, HSU SM, WIJDENES J etal: Brief report: alleviation of systemic manifestations of Castleman's disease by monoclonal anti-interleukin-6 antibody. N Engl. J. Med. (1994) 330 (9):602-605.
150. WENDLING D, RACADOT E, WIJDENES J: Treatment of severe rheumatoid arthritis by anti-interleukin 6 monoclonal antibody. J. Rheumatol. (1993) 20 (2):259-262.
151. MONTERO-JULIAN FA, KLEIN B, GAUTHEROT E, BRAILLY H: Pharmacokinetic study of anti-interleukin-6 (IL-6) therapy with monoclonal antibodies: enhancement of IL-6 clearance by cocktails of anti-IL6 antibodies. Blood (1995) 85 (4):917-924.
152. VAN ZAANEN HC, KOOPMANS RP, AARDEN LA et al: Endogenous interleukin 6 production in multiple myeloma patients treated with chimeric monoclonal anti-IL6 antibodies indicates the existence of a positive feed-back loop. J. Clin. Invest. (1996) 98(6):1441-1448.
153. VAN ZAANEN HC, LOKHORST HM, AARDEN LA et al: Blocking interleukin-6 activity with chimeric anti-IL6 monoclonal antibodies in multiple myeloma: effects on soluble IL6 receptor and soluble gp130. Leukemia Lymphoma (1998) 31 (5-6):551-558.
154. VAN ZAANEN HC, LOKHORST HM, AARDEN LA et al: Chimaeric anti-interleukin 6 monoclonal antibodies in the treatment of advanced multiple myeloma: a Phase I dose-escalating study. Br. J. Haematol. (1998) 102 (3)783-790.
155. YOSHIZAKIK, NISHIMOTO N, MIHARA M, KISHIMOTO T: Therapy of rheumatoid arthritis by blocking IL-6 signal transduction with a humanized anti-IL-6 receptor antibody. Springer Semin. Immunopathol (1998) 20(1-2):247-259.
156. NISHIMOTO N, KISHIMOTO T, YOSHIZAKI K: Anticyto-kine therapy in autoimmune diseases. Intern. Med. (1999) 38(2):178-182.
157. NISHIMOTO N, SASAI M, SHIMA Y etal: Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy. Blood (2000) 95 (1):56-61.
158. RENNE C, KALLEN KJ, MULLBERG J et al: Anew type of cytokine receptor antagonist directly targeting gp130. J. Biol. Chem. (1998) 273 (42):27213-27219.
159. SANDS BE, BANK S, SNINSKY CA et al: Preliminary evaluation of safety and activity of recombinant human interleukin 11 in patients with active Crohn's disease. Gastroenterology (1999) 117 (1):58-64.
160. TREPICCHIO WL, OZAWA M, WALTERS IB et al.: Interleukin-11 therapy selectively downregulates Type I cytokine proinflammatory pathways in psoriasis lesions.J. Clin. Invest. (1999) 104(11):1527-1537.
161. TAKEDA K, CLAUSEN BE, KAISHO T etal: Enhanced Th1 activity and development of chronic enterocolitis in mice devoid of Stat3 in macrophages and neutrophils. Immunity (1999) 10 (1):39-49.
162. A double-blind placebo-controlled clinical trial of subcutaneous recombinant human ciliary neurotrophic factor (rHCNTF) in amyotrophic lateral sclerosis. ALS CNTF Treatment Study Group. Neurology (1996) 46 (5):1244-1249.
163. AEBISCHER P, SCHLUEP M, DEGLON N etal.: Intrathecal delivery of CNTF using encapsulated genetically modified xenogeneic cells in amyotrophic lateral sclerosis patients. Nature Med. (1996) 2 (6):696-699.
164. PENN RD, KROIN JS, YORK MM, CEDARBAUM JM: Intrathecal ciliary neurotrophic factor delivery for treatment of amyotrophic lateral sclerosis (phase I trial). Neurosurgery(1997) 40(1):94-99; discussion99-100.
165. KOBAYASHI M, FITZ L, RYAN M etal.: Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes.J. Exp. Med. (1989) 170 (3):827-845.
166. DAVIS S, ALDRICH TH, IP NY et al.: Released form of CNTF receptor (X components as a soluble mediator of CNTF responses. Science (1993) 259:1736-1739.
167. BAUMANN H, WANG Y, MORELLA KK etal: Complex of the soluble IL-11 receptor and IL-11 acts as IL-6-type cytokine in hepatic and nonhepatic cells. J. Immunol (1996) 157 (1):284-290.
168. NEDDERMANN P, GRAZIANI R, CILIBERTO G, PAONESSA G: Functional expression of soluble human interleukin-11 (IL-11) receptor a and stoichiometry of in vitro IL-11 receptor complexes with gp130. J. Biol Chem. (1996) 271 (48):30986-30991.
169. HIRANO T, MATSUDA T, NAKAJIMA K: Signal transduction through gp130 that is shared amongthe receptors for the interleukin 6 related cytokine subfamily. Stem Cells (1994) 12 (3):262-277.
170. HIRANO T: Molecular basis underlying functional pleiotropy of cytokines and growth factors. Biochem. Biophys. Res. Commun. (1999) 260(2):303-308.
171. HIROTA H, YOSHIDA K, KISHIMOTO T, TAGA T: Continuous activation of gp130, a signal transducing receptor component for interleukin 6-related cytokines, causes myocardial hypertrophy in mice. Proc. Natl. Acad. Sci. USA (1995) 92:4862-4866.
172. FISCHER M, GOLDSCHMITT J, PESCHEL C et al: I. A bioactive designer cytokine for human hematopoietic progenitor cell expansion. Nature Biotechnol. (1997) 15 (2):142-145.
173. PETERS M, MULLER AM, ROSE-JOHN S: Interleukin-6 and soluble interleukin-6 receptor: direct stimulation of gp130 and hematopoiesis. Blood (1998) 92(10):3495-3504.
174. SOBOTA R, SZWED M, KASZA A, BUGNO M, KORDULA T: Parthenolide inhibits activation of signal transducers and activators of transcription (STATs) induced by cytokines of the IL-6 family. Biochem. Biophys. Res. Commun. (2000) 267(1):329-333.
175. BORK PM, SCHMITZ ML, KUHNT M, ESCHER C, HEINRICH M: Sesquiterpene lactone containing Mexican Indian medicinal plants and pure sesquiterpene lactones as potent inhibitors of transcription factor NF-κB. FEBS Lett. (1997) 402(1):85-90.
176. DURIE BGM, GILES FJ: Myeloma and other proteinae-mias. In: Oxford Textbook of Medicine (3rd Edition). Weatherall DJ, Ledingham JGG, Warell DA (Eds.), Oxford University Press, New York, USA (1996):3597-3605.
177. BUNCH C, GATTER KC: The lymphomas. In: Oxford Textbook of Medicine (3rd Edition). Weatherall DJ, Ledingham JGG, Warell DA (Eds.), Oxford University Press, New York, USA (1996):3568-3587.
178. TRAILL TA: Cardiac myxoma. In: Oxford Textbook of Medicine (3rd Edition). Weatherall DJ, Ledingham JGG, Warell DA (Eds.), Oxford University Press, New York, USA (1996):2472-2474.
179. WORDSWORTH BP: Rheumatoid arthritis. In: Oxford Textbook of Medicine (3rd Edition). Weatherall DJ, Ledingham JGG, Warell DA (Eds.), Oxford University Press, New York, USA (1996):2953-2965.
180. WILLIAMS DG: Mesangiocapillary glomerulonephritis. In: Oxford Textbook of Clinical Nephrology (2nd Edition). Davison AM, Cameron JS, Grunfeld J-P, Kerr DNS, Ritz E, Winearls CG (Eds.), Oxford University Press, New York, USA (1998):591-612.
181. JEWELL DP: Crohn's disease. In: Oxford Textbook of Medicine (3rd Edition). Weatherall DJ, Ledingham JGG, Warell DA (Eds.), Oxford University Press, New York, USA (1996):1936-1943.
182. RYAN TJ: Diseases of the skin. In: Oxford Textbook of Medicine (3rd Edition). Weatherall DJ, Ledingham JGG, Warell DA (Eds.), Oxford University Press, New York, USA (1996):3705-3811.
183. SEARS MR: Epidemiology. In: Asthma Basic Mechanism and Clinical Management (2nd Edition). Barnes PJ, Rodger IW, Thomson NC (Eds.), Academic Press, San Diego, USA (1992):1-19.
184. DONAGHY M: The motor neurone diseases. In: Oxford Textbook of Medicine (3rd Edition). Weatherall DJ, Ledingham JGG, Warell DA (Eds.), Oxford University Press, New York, USA (1996):4087-4090.
185. RAMSAY AJ, HUSBAND AJ, RAMSHAW IAet al.: The roleof interleukin-6 in mucosal IgA antibody responses in vivo. Science (1994) 264(5158):561-563.
186. BERNAD A, KOPF M, KULBACKI R et al.: Interleukin-6 is required in vivo for the regulation of stem cells and committed progenitors of the hematopoietic system. Immunity (1994) 1(9):725-731.
187. CRESSMAN DE, GREENBAUM LE, DEANGELIS RA et al.: Liver failure and defective hepatocyte regeneration in interleukin-6-deficient mice. Science (1996) 274 (5291):1379-1383.
188. POLI V, BALENA R, FATTORI E et al: Interleukin-6 deficient mice are protected from bone loss caused by estrogen depletion. EMBO J. (1994) 13 (5):1189-1196.
189. FATTORI E, DELLA ROCCA C, COSTA P et al: Development of progressive kidney damage and myeloma kidney in interleukin-6 transgenic mice. Blood (1994) 83 (9):2570-2579.
190. PETERS M, JACOBS S, EHLERS M etal.: The function of the soluble interleukin 6 (IL-6) receptor in vivo: sensitization of human soluble IL-6 receptor transgenic mice towards IL 6 and prolongation of the plasma half-life of IL6. J. Exp. Med. (1996) 183 (4):1399-1406.
191. SCHIRMACHER P, PETERS M, CILIBERTO G etal.: Hepato cellular hyperplasia, plasmacytoma formation and extramedullary hematopoiesis in interleukin (IL)-6/soluble IL6 receptor double-transgenic mice. Am. J. Pathol (1998) 153 (2):639-648.
192. TANG W, GEBA GP, ZHENG T etal.: Targeted expression of IL11 in the murine airway causes lymphocytic inflammation, bronchial remodeling and airways obstruction.J. Clin. Invest. (1996) 98(12):2845-2853.
193. RAY P, TANG W, WANG P et al: Regulated overexpres-sion of interleukin 11 in the lung. Use to dissociate development-dependent and-independent phenotypes.J. Clin. Invest. (1997) 100 (10):2501-2511.
194. STEWART CL, KASPAR P, BRUNET LJ et al: Blastocyst implantation depends on maternal expression of leukaemia inhibitory factor. Nature (1992) 359 (6390):76-79.
195. TOLOSANO E, CUTUFIA MA, HIRSCH E et al: Ciliary neurotrophic factor constitutively expressed in the nervous system of transgenic mice protects embryonic dorsal root ganglion neurons from apoptosis. Eur. J. Neurosci. (1996) 8 (3):521-529.
196. WINTER CG, SAOTOME Y, LEVISON SW, HIRSH D: Arole for ciliary neurotrophic factor as an inducer of reactive gliosis, the glial response to central nervous system injury. Proc. Natl. Acad. Sci. USA (1995) 92 (13):5865-5869.
197. RODIG SJ, MERAZ MA, WHITE JM et al: Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses. Cell (1998) 93 (3):373-383.
198. NEUBAUER H, CUMANO A, MULLER M et al: Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis. Cell (1998) 93 (3):397-409.
199. PARGANAS E, WANG D, STRAVOPODIS D et al: Jak2 is essential for signaling through a variety of cytokine receptors. Cell (1998) 93 (3):385-395.
200. SAXTON TM, HENKEMEYER M, GASCA S et al: Abnormal mesoderm patterning in mouse embryos mutant for the SH2 tyrosine phosphatase Shp-2. EMBO J. (1997) 16 (9):2352-2364.
201. TAKEDA K, NOGUCHI K, SHI W et al: Targeted disrup tion of the mouse Stat3 gene leads to early embryonic lethality. Proc. Natl. Acad. Sci. USA (1997) 94(8):3801-3804.
202. NAKA T, MATSUMOTO T, NARAZAKI M et al: Accelerated apoptosis of lymphocytes by augmented induction of Bax in SSI-1 (STAT-induced STATinhibitor-1) deficient mice. Proc. Natl. Acad. Sci. USA (1998) 95 (26):15577-15582.